Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulindac

FDA-approved product (tablet, oral), marketed as Clinoril, Sulindac.

Registered studies
40
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulindac
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Osteoarthritis
  • Rheumatic disease
  • Rheumatoid arthritis
  • Spondylitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Acetic acid derivatives and related substances
FDA pharmacologic class
Nonsteroidal Anti-inflammatory Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulindac in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulindac with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

    NCT00755976 · start 2007-08

    Registered record
    Registry ID
    NCT00755976
    Conditions
    Melanoma (Skin)
    Interventions
    epirubicin hydrochloride; sulindac; immunologic technique
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-05
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma (Skin)
    Interventionepirubicin hydrochloride; sulindac; immunologic technique
    PhasePhase 2
    Registry statusCompleted

  • Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

    NCT00392665 · start 2006-10

    Registered record
    Registry ID
    NCT00392665
    Conditions
    Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Interventions
    Bevacizumab; erlotinib; Sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-10
    Completion
    2013-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck (SCCHN)
    InterventionBevacizumab; erlotinib; Sulindac
    PhasePhase 2
    Registry statusTerminated

  • Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

    NCT00368927 · start 2006-08

    Registered record
    Registry ID
    NCT00368927
    Conditions
    Precancerous Condition; Stage I Non-small Cell Lung Cancer; Tobacco Use Disorder
    Interventions
    sulindac; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2010-12
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecancerous Condition; Stage I Non-small Cell Lung Cancer; Tobacco Use Disorder
    Interventionsulindac; placebo
    PhasePhase 2
    Registry statusCompleted

  • Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis

    NCT00319007 · start 2006-04

    Registered record
    Registry ID
    NCT00319007
    Conditions
    Adenomatous Polyposis Coli
    Interventions
    Sulindac (drug); VSL#3 (probiotic); Inulin (probiotic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2006-04
    Completion
    2006-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomatous Polyposis Coli
    InterventionSulindac (drug); VSL#3 (probiotic); Inulin (probiotic)
    PhasePhase 2
    Registry statusUnknown

  • Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers

    NCT00343629 · start 2006-04

    Registered record
    Registry ID
    NCT00343629
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sulindac; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-10
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionsulindac; pharmacological study
    PhaseNot applicable
    Registry statusCompleted

  • Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

    NCT00335504 · start 2006-03

    Registered record
    Registry ID
    NCT00335504
    Conditions
    Colon Cancer; Precancerous Condition; Rectal Cancer
    Interventions
    oligofructose-enriched inulin; sulindac; placebo; atorvastatin calcium; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03
    Completion
    2009-04
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer; Precancerous Condition; Rectal Cancer
    Interventionoligofructose-enriched inulin; sulindac; placebo; atorvastatin calcium +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Study of Sulindac in Oral Premalignant Lesions

    NCT00299195 · start 2006-02-23

    Registered record
    Registry ID
    NCT00299195
    Conditions
    Leukoplakia, Oral; Benign Neoplasms
    Interventions
    sulindac; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-02-23
    Completion
    2020-01-06
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukoplakia, Oral; Benign Neoplasms
    Interventionsulindac; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer

    NCT00245024 · start 2005-11

    Registered record
    Registry ID
    NCT00245024
    Conditions
    Breast Cancer
    Interventions
    sulindac; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    2010-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionsulindac; laboratory biomarker analysis
    PhasePhase 1
    Registry statusCompleted

  • Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

    NCT01515137 · start 2005-11

    Registered record
    Registry ID
    NCT01515137
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    Erlotinib; Erlotinib plus sulindac; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    2014-09
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionErlotinib; Erlotinib plus sulindac; Placebo
    PhasePhase 1
    Registry statusCompleted

  • The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

    NCT00176618 · start 2004-04

    Registered record
    Registry ID
    NCT00176618
    Conditions
    Aberrant Crypt Foci
    Interventions
    sulindac; curcumin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2004-04
    Completion
    2007-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAberrant Crypt Foci
    Interventionsulindac; curcumin
    PhaseNot applicable
    Registry statusTerminated

  • Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

    NCT00068419 · start 2004-02

    Registered record
    Registry ID
    NCT00068419
    Conditions
    Desmoid Tumor
    Interventions
    tamoxifen citrate; sulindac; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2010-04-26
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDesmoid Tumor
    Interventiontamoxifen citrate; sulindac; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

    NCT00078910 · start 2003-08

    Registered record
    Registry ID
    NCT00078910
    Conditions
    Prostate Cancer
    Interventions
    exisulind; conventional surgery; neoadjuvant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-08
    Completion
    2006-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionexisulind; conventional surgery; neoadjuvant therapy
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

    NCT00062023 · start 2003-06

    Registered record
    Registry ID
    NCT00062023
    Conditions
    Colorectal Cancer
    Interventions
    Acetylsalicylic acid (Aspirin); Sulindac; Ursodiol; Sulindac Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-06
    Completion
    2006-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionAcetylsalicylic acid (Aspirin); Sulindac; Ursodiol; Sulindac Placebo
    PhasePhase 2
    Registry statusTerminated

  • Exisulind Versus Placebo After Surgical Removal of the Prostate

    NCT00166426 · start 2003-02

    Registered record
    Registry ID
    NCT00166426
    Conditions
    Prostatic Neoplasms
    Interventions
    Exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-02
    Completion
    2008-05
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionExisulind
    PhasePhase 2
    Registry statusCompleted

  • Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

    NCT00052845 · start 2002-11

    Registered record
    Registry ID
    NCT00052845
    Conditions
    Prostate Cancer
    Interventions
    docetaxel; estramustine phosphate sodium; exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-11
    Completion
    2009-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventiondocetaxel; estramustine phosphate sodium; exisulind
    PhasePhase 2
    Registry statusCompleted